CAR T-Cell Therapy cost in India
CAR T-cell therapy cost in India can range from $45000 to $85000, which is equivalent to approximately 38,50,000 to 75,00,000 Indian rupees. CAR T-cell therapy is an advanced treatment where a patient's T cells, which are crucial to the immune system, are altered in a lab to specifically target and destroy cancer cells.
The process begins with extracting T cells from the patient's blood, which are then genetically engineered to display chimeric antigen receptors (CARs) on their surface. After modification, these CAR T cells are multiplied in the lab and reintroduced into the patient's body via infusion. This therapy is uniquely personalized for each patient and has shown great success in treating difficult cancers like leukemia and lymphoma. Ongoing research explores its potential to treat other cancer types.
Cost Range of CAR T-Cell Therapy cost in India
Cost Inclusions:
CAR T-cell therapy development
Lab charges
Hospital stay for recommended days
Airport pick up and drop
Doctor's fee and consultation
Get a free cost estimate
CAR T-cell therapy offers the advantage of a shorter treatment duration compared to traditional cancer therapies. It provides long-term remission and an improved quality of life for patients, often surpassing conventional approaches. Unlike stem cell transplants, which involve intensive chemotherapy, CAR T-cell therapy generally results in a quicker recovery for most patients.
Additionally, CAR T-cells differ from Tumor Infiltrating Lymphocytes (TILs) and T Cell Receptors (TCRs) as they do not rely on Major Histocompatibility Complex (MHC) expression for antigen recognition. This unique ability allows CAR T-cells to recognize specific antigens independently of antigen processing by the target cells and MHC restrictions, leading to more effective tumor cell destruction.
Who is a candidate for CAR T-cell therapy in India?
In India, candidates for CAR T-cell therapy are typically patients with certain types of cancers that have not responded to conventional treatments, such as chemotherapy or radiation. The most common cancers for which CAR T-cell therapy is currently approved include:
Relapsed or Refractory Blood Cancers
Patients with certain types of blood cancers, such as B-cell acute lymphoblastic leukemia (ALL) in children and young adults, and certain types of non-Hodgkin lymphoma (NHL) like diffuse large B-cell lymphoma (DLBCL), who have not responded to standard treatments, may be considered.
Eligibility Criteria
- Disease Status: The patient should have relapsed or refractory disease after at least two prior lines of therapy.
- Health Condition: The patient should be in a reasonably good health condition to withstand the treatment, as CAR T-cell therapy can cause side effects in certain patients, including cytokine release syndrome (CRS) and neurological toxicities.
- Medical Evaluation: A thorough medical evaluation is conducted to assess whether the patient is a suitable candidate, including considering factors like the patient's overall health, comorbidities, and prior treatment history.
- Availability: As CAR T-cell therapy is relatively new in India, it is mostly available through specialized cancer centers. Patients should consult with oncologists at institutions offering CAR T-cell therapy to determine if they are eligible.
Types of CAR T-Cell Therapy Treatment Cost
Type of FDA Approved CAR T-Cell Therapy in India | Diagnosis | Cost Range in USD |
Kymriah | B-Cell Acute Lymphoblastic Leukemia (ALL)B-Cell Non-Hodgkin's Lymphoma (NHL) | 65000 - 85000 |
Yescarta | B-Cell Non-Hodgkin's Lymphoma (NHL)Follicular Lymphoma | 65000 - 85000 |
Tecartus | Mantle Cell Lymphoma (MCL)B-Cell Acute Lymphoblastic Leukemia (ALL) | 65000 - 85000 |
Breyanzi | B-Cell Non-Hodgkin's Lymphoma (NHL) | 65000 - 85000 |
Abecma | Multiple Myeloma | 45000 - 65000 |
Carvykti | Multiple Myeloma | 45000 - 65000 |
Get a free cost estimate
CAR T-Cell Therapy Cost in India Inclusions
CAR T-cell therapy infusions
Routine medicines and consumables required during treatment
CAR T-Cell Therapy Cost in India Exclusions
Pre-treatment examination and tests related to staging of cancer
Meals and flights
Hospital and hotel stay
Post-treatment follow-ups and management
Treatment for any other underlying medical conditions
Any complex investigations or medicines
Anything not covered in the package
Other Factors Affecting CAR T-Cell Therapy Cost in India
Age of the patient and symptoms
Type of blood cancer (how much it has spread)
Stage and grade of cancer
Pre-existing medical history
Recommended treatment and duration
Number and type of treatment modalities advised
Diagnostic Tests Required Before CAR T-Cell Therapy Treatment
Types of Tests For CAR T-Cell Therapy Treatment in India | Cost Range in USD |
Blood tests These include the basic blood investigations for the patient to check organ functioning, infection status and coagulation profile. | 50 to 100 |
Radiological Assessment MRI, CT or any other tests to check for location of the disease. This may also include an endoscopic ultrasound (EUS). | 150 to 250 |
Histopathology Examination This includes tests such as biopsy for examination under a microscope. | 150 to 250 |
Full Body PET Scan This includes a full body PET FDG scan to check for an metastasis and establish the stage of the cancer. | 400 to 600 |
Assessment for Cytokine Release Syndrome (CRS)Although not a diagnostic test, understanding the risk of CRS and preparing for its management is crucial. Cardiac and pulmonary assessment is also planned alongside. | 100 to 150 |
Why is India preferred as one of the best countries for CAR T-Cell Therapy Treatment?
India is becoming a preferred destination for CAR T-cell therapy due to several compelling reasons. The treatment is often more cost-effective in India compared to Western countries, making it accessible to a broader range of patients. Additionally, India boasts advanced medical facilities equipped with state-of-the-art technology and skilled professionals who specialize in CAR T-cell therapy.
Indian oncologists have extensive experience and expertise gained through global collaborations and research, ensuring high-quality care. Comprehensive patient care, including thorough pre-treatment evaluations, personalized treatment plans, and robust post-treatment support, is a hallmark of Indian hospitals. The country also serves as a hub for clinical trials, providing access to the latest therapies. Furthermore, India offers multilingual services and patient-centric care, which are advantageous for international patients. Favorable regulations and streamlined processes for medical visas and treatment approvals further facilitate access to this advanced treatment. These factors collectively enhance India's reputation as a leading destination for CAR T-cell therapy.